RxDoctor Payments DataLook up a doctor →

John Rothrock, MD

Neurology · Fairfax, VANPI 1174577449

Payments from drug & device makers

$504,018in general payments, 2019–2025

Across 466 payments — averaging $1081.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$299K
  • Ipsen Innovation$55K
  • Amgen$39K
  • Lundbeck LLC$38K
  • H. Lundbeck A S$28K
  • Impel Pharmaceuticals Inc.$16K
  • plus $29K from 11 others

What the payments were for

  • Consulting fees$36,32816%
  • Speaking & faculty fees$172,76377%
  • Travel & lodging$8,3284%
  • Food & beverage$7,4403%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$504,018 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$23,409
Medicare patients
88
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate53$103,430
QuliptaAtogepant34$54,275
UbrelvyUbrogepant15$20,360
MounjaroTirzepatide11$12,898
Sumatriptan Succinate61$4,575
Levetiracetam12$892
RizatriptanRizatriptan Benzoate30$700
Memantine Hcl23$552
Donepezil Hcl72$453
Levetiracetam ErLevetiracetam15$402
Naproxen Sodium16$401
Atorvastatin Calcium15$400
Celecoxib26$380
Citalopram HbrCitalopram Hydrobromide29$258
Gabapentin22$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$3,638$103,43053 claims
AbbVieQulipta, Ubrelvy$298,724$74,63649 claims
Lilly USA, LLCMounjaro$8,309$12,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →